{"id":41433,"date":"2024-03-14T14:18:33","date_gmt":"2024-03-14T14:18:33","guid":{"rendered":"https:\/\/conseil-concurrence.preprod.io\/communique-du-conseil-de-la-concurrence-relatif-au-projet-de-concentration-economique-qui-concerne-lacquisition-par-la-societe-hikma-pharmaceuticals-plc-dune-activite-m-2\/"},"modified":"2026-02-06T14:27:33","modified_gmt":"2026-02-06T14:27:33","slug":"press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi","status":"publish","type":"post","link":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/","title":{"rendered":"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d."},"content":{"rendered":"<p>In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties.<\/p>\n<p>This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation.<\/p>\n<p>The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n<p><strong>Names of the companies and groups concerned:<\/strong><\/p>\n<ul>\n<li><strong>The acquirer<\/strong>: the company \u201cHikma Pharmaceuticals PLC\u201d.<\/li>\n<li><strong>The target<\/strong>: The pharmaceutical activity related to products (bleomycin) of the company \u201cSanofi SA\u201d.<\/li>\n<\/ul>\n<p><strong>Nature of the operation<\/strong><\/p>\n<ul>\n<li>The acquisition of certain assets and rights.<\/li>\n<\/ul>\n<p><strong>Economic sectors concerned<\/strong><\/p>\n<ul>\n<li>Pharmaceutical sector.<\/li>\n<\/ul>\n<p><strong>Deadline for interested third parties to submit their observations<\/strong><\/p>\n<ul>\n<li>10 days from the date of publication of this press release, i.e. March 25, 2024.<\/li>\n<\/ul>\n<p><strong>NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n<p>The Competition Council received notification of an economic concentration operation concerning the acquisition by the company \u201cHikma Pharmaceuticals PLC\u201d (Hikma) of the exclusive control of the pharmaceutical activity related to products (Bleomycin) from the company \u201cSanofi SA\u201d.<\/p>\n<p>\u201cHikma\u201d is an international pharmaceutical company headquartered in the United Kingdom, manufacturing and distributing a wide range of generic products and brands, including injectable products and specialized medicines.<\/p>\n<p>\u201cSanofi SA\u201d is a global pharmaceutical company based in France, dedicated to research, development, manufacturing, distribution, and promotion of therapeutic solutions for patients worldwide. \u201cSanofi SA\u201d is structured into two main business units: Biopharma and Consumer Healthcare.<\/p>\n<p style=\"text-align: right;\">Done in Rabat on March 14, 2024.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: The acquirer: the company \u201cHikma Pharmaceuticals PLC\u201d. The target: The pharmaceutical activity related to products (bleomycin) of the company \u201cSanofi SA\u201d. Nature of the operation The acquisition of certain assets and rights. Economic sectors concerned Pharmaceutical sector. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e. March 25, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the acquisition by the company \u201cHikma Pharmaceuticals PLC\u201d (Hikma) of the exclusive control of the pharmaceutical activity related to products (Bleomycin) from the company \u201cSanofi SA\u201d. \u201cHikma\u201d is an international pharmaceutical company headquartered in the United Kingdom, manufacturing and distributing a wide range of generic products and brands, including injectable products and specialized medicines. \u201cSanofi SA\u201d is a global pharmaceutical company based in France, dedicated to research, development, manufacturing, distribution, and promotion of therapeutic solutions for patients worldwide. \u201cSanofi SA\u201d is structured into two main business units: Biopharma and Consumer Healthcare. Done in Rabat on March 14, 2024.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-41433","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d. - Conseil de la concurrence du Maroc<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d. - Conseil de la concurrence du Maroc\" \/>\n<meta property=\"og:description\" content=\"In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: The acquirer: the company \u201cHikma Pharmaceuticals PLC\u201d. The target: The pharmaceutical activity related to products (bleomycin) of the company \u201cSanofi SA\u201d. Nature of the operation The acquisition of certain assets and rights. Economic sectors concerned Pharmaceutical sector. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e. March 25, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the acquisition by the company \u201cHikma Pharmaceuticals PLC\u201d (Hikma) of the exclusive control of the pharmaceutical activity related to products (Bleomycin) from the company \u201cSanofi SA\u201d. \u201cHikma\u201d is an international pharmaceutical company headquartered in the United Kingdom, manufacturing and distributing a wide range of generic products and brands, including injectable products and specialized medicines. \u201cSanofi SA\u201d is a global pharmaceutical company based in France, dedicated to research, development, manufacturing, distribution, and promotion of therapeutic solutions for patients worldwide. \u201cSanofi SA\u201d is structured into two main business units: Biopharma and Consumer Healthcare. Done in Rabat on March 14, 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/\" \/>\n<meta property=\"og:site_name\" content=\"Conseil de la concurrence du Maroc\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-14T14:18:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T14:27:33+00:00\" \/>\n<meta name=\"author\" content=\"Youssef OTMANE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Youssef OTMANE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/\"},\"author\":{\"name\":\"Youssef OTMANE\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\"},\"headline\":\"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d.\",\"datePublished\":\"2024-03-14T14:18:33+00:00\",\"dateModified\":\"2026-02-06T14:27:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/\"},\"wordCount\":339,\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/\",\"name\":\"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d. - Conseil de la concurrence du Maroc\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#website\"},\"datePublished\":\"2024-03-14T14:18:33+00:00\",\"dateModified\":\"2026-02-06T14:27:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\",\"name\":\"Conseil de la concurrence du Maroc\",\"description\":\"Conseil de la concurrence\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/#\\\/schema\\\/person\\\/24b4bd1e24ccf3057c8fcb57662a0b81\",\"name\":\"Youssef OTMANE\",\"url\":\"https:\\\/\\\/conseil-concurrence.ma\\\/en\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d. - Conseil de la concurrence du Maroc","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/","og_locale":"en_US","og_type":"article","og_title":"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d. - Conseil de la concurrence du Maroc","og_description":"In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council&#8217;s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: The acquirer: the company \u201cHikma Pharmaceuticals PLC\u201d. The target: The pharmaceutical activity related to products (bleomycin) of the company \u201cSanofi SA\u201d. Nature of the operation The acquisition of certain assets and rights. Economic sectors concerned Pharmaceutical sector. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e. March 25, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the acquisition by the company \u201cHikma Pharmaceuticals PLC\u201d (Hikma) of the exclusive control of the pharmaceutical activity related to products (Bleomycin) from the company \u201cSanofi SA\u201d. \u201cHikma\u201d is an international pharmaceutical company headquartered in the United Kingdom, manufacturing and distributing a wide range of generic products and brands, including injectable products and specialized medicines. \u201cSanofi SA\u201d is a global pharmaceutical company based in France, dedicated to research, development, manufacturing, distribution, and promotion of therapeutic solutions for patients worldwide. \u201cSanofi SA\u201d is structured into two main business units: Biopharma and Consumer Healthcare. Done in Rabat on March 14, 2024.","og_url":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/","og_site_name":"Conseil de la concurrence du Maroc","article_published_time":"2024-03-14T14:18:33+00:00","article_modified_time":"2026-02-06T14:27:33+00:00","author":"Youssef OTMANE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Youssef OTMANE","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/#article","isPartOf":{"@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/"},"author":{"name":"Youssef OTMANE","@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81"},"headline":"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d.","datePublished":"2024-03-14T14:18:33+00:00","dateModified":"2026-02-06T14:27:33+00:00","mainEntityOfPage":{"@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/"},"wordCount":339,"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/","url":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/","name":"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d. - Conseil de la concurrence du Maroc","isPartOf":{"@id":"https:\/\/conseil-concurrence.ma\/en\/#website"},"datePublished":"2024-03-14T14:18:33+00:00","dateModified":"2026-02-06T14:27:33+00:00","author":{"@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81"},"breadcrumb":{"@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/conseil-concurrence.ma\/en\/press-release-from-the-competition-council-regarding-the-economic-concentration-project-concerning-the-acquisition-by-the-company-hikma-pharmaceuticals-plc-of-a-pharmaceutical-activi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/conseil-concurrence.ma\/en\/"},{"@type":"ListItem","position":2,"name":"Press release from the Competition Council regarding the economic concentration project concerning the acquisition by the company \u201cHIKMA PHARMACEUTICALS PLC\u201d of a pharmaceutical activity related to products (bleomycin) from \u201cSANOFI SA\u201d."}]},{"@type":"WebSite","@id":"https:\/\/conseil-concurrence.ma\/en\/#website","url":"https:\/\/conseil-concurrence.ma\/en\/","name":"Conseil de la concurrence du Maroc","description":"Conseil de la concurrence","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/conseil-concurrence.ma\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/conseil-concurrence.ma\/en\/#\/schema\/person\/24b4bd1e24ccf3057c8fcb57662a0b81","name":"Youssef OTMANE","url":"https:\/\/conseil-concurrence.ma\/en\/"}]}},"_links":{"self":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/comments?post=41433"}],"version-history":[{"count":1,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41433\/revisions"}],"predecessor-version":[{"id":45124,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/posts\/41433\/revisions\/45124"}],"wp:attachment":[{"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/media?parent=41433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/categories?post=41433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/conseil-concurrence.ma\/en\/wp-json\/wp\/v2\/tags?post=41433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}